Direct recognition and lysis of leukemia cells by WT1-specific CD4 + T lymphocytes in an HLA class II-restricted manner

Blood

Volumn 106, Issue 4, 2005, Pages 1415-1418

  Guo, Yun ^b   Niiya, Hironari ^b   Azuma, Taichi ^b   Uchida, Naoyuki ^b   Yakushijin, Yoshihiro ^b   Sakai, Ikuya ^b   Hato, Takaaki ^b   Takahashi, Masuhiro ^b   Senju, Satoru ^b   Nishimura, Yasuharu ^b   Yasukawa, Masaki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DP5 ANTIGEN; LEUCYLSERYLHISTIDYLLEUCYLGLUTAMYLMETHIONYLHISTIDYLSERYLARGINYLLYSYLHISTIDIN E; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW CELL; COLONY FORMATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IN VITRO STUDY; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL;

EID: 23744460167     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0413     Document Type: Article

References (22)

1. Xue S, Gao L, Gillmore R, et al. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis. 2004;33:288-290.
2. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17:1301-1312.
3. Sugiyama H. Cancer immunotherapy targeting WT1 protein. Int J Hematol. 2002;76:127-132.
4. Yasukawa M. Immunotherapy for leukemia targeting the Wilms' tumor gene. Leuk Lymphoma. 2001;42:267-273.
5. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
6. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99-107.
7. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
8. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
9. Doubrovina ES, Doubrovin MM, Lee S, et al. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res. 2004;10:7207-7219.
10. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-13890.
11. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-166.
12. + T cells in antitumor immunity. Trends Immunol. 2001;22:269-276.
13. + cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood. 1998;92:3355-3361.
14. + human cytotoxic T cell clones directed against herpes simplex virus. J Immunol. 1988;140:3419-3425.
15. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2002;8:2626-2631.
16. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-3079.
17. + T cell help. J Exp Med. 1997;186:65-70.
18. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
19. Yasukawa M, Zarling JM. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells, I: lysis restricted by HLA class II MB and DR antigens. J Immunol. 1984;133:422-427.
20. Jellison ER, Kim SK, Welsh RM. MHC class II-restricted killing in vivo during viral infection. J Immunol. 2005;174:614-618.
21. + T lymphocytes. J Immunol. 1998;160:661-666.
22. Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 2003;17:707-715.